{
    "nctId": "NCT00174434",
    "briefTitle": "Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer",
    "officialTitle": "A Phase 1 Study Of Paclitaxel In Combination With SU011248 For Patients With Breast Cancer As First-Line Treatment In The Advanced Disease Setting",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 22,
    "primaryOutcomeMeasure": "Safety of the combination of SU011248 and paclitaxel",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Breast cancer with evidence of unresectable, locally recurrent or metastatic disease.\n* Candidate for treatment with paclitaxel.\n\nExclusion Criteria:\n\n* Prior chemotherapy in the advanced disease setting.\n* HER2 positive disease unless previously treated with trastuzumab.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}